Osteoporosis drug study shows promising results
Osteoporosis drug study shows promising results
A Canadian study has shown promising results for the prevention of bone loss in osteoporosis patients receiving corticosteroid therapy. From a placebo-controlled study of 141 patients at McMaster University (Hamilton, Ontario), in which half received the drug etidronate (Didronel) followed by calcium during a year’s time, new vertebral fractures in the post-menopausal patients were reduced by 85% compared with patients on placebo, while overall patient group reduction was almost 50%, according to the research.
Etidronate was given in four cycles during the study, and researchers also noted a small increase in bone density in some cases. Researchers also say the therapy was well tolerated overall, and a follow-up study is being planned.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.